AstraZeneca cancelled its £450m expansion in Liverpool, while GSK announced a £400m investment in a new R&D center and relocated scientists from Stevenage.

1 report, 1 independent Updated Jul 28

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

GSK AstraZeneca

Keep exploring

Part of

GSK is undergoing major operational shifts regarding its sites, including upgrading the Ware facility, opening a new flagship site in Cambridge, and shutting down its main R&D hub in Stevenage. All 2 developments

The entities involved

GSK
British multinational pharmaceutical and biotechnology company
- Clement Fourny joins Biodextris as CEO, a company that originated as a GSK development center.Mon 15:26
- GSK acquired Sierra Oncology.Mon 14:28
AstraZeneca
British-Swedish pharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
- Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52

Related events

Chinese pharmaceutical companies are investing heavily in novel technologies while AstraZeneca confirms its Cambridge headquarters and CEO.Jul 27

Coverage

Newest first; wire copies grouped

Jul 28theguardian.comGSK heads to Cambridge with long-awaited positive vibes | Nils Pratley